These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 11912297)

  • 1. Determinants of uraemic toxin removal.
    Clark WR; Gao D
    Nephrol Dial Transplant; 2002; 17 Suppl 3():30-4. PubMed ID: 11912297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genesis of the uraemic syndrome: role of uraemic toxins.
    Hörl WH
    Wien Klin Wochenschr; 1998 Aug; 110(15):511-20. PubMed ID: 9782569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ultimate salt war? Uraemic toxins are all that count in dialysis patients.
    Vanholder R
    Nephrol Dial Transplant; 2012 Jan; 27(1):62-6. PubMed ID: 22287703
    [No Abstract]   [Full Text] [Related]  

  • 4. Intradialytic removal of protein-bound uraemic toxins: role of solute characteristics and of dialyser membrane.
    Lesaffer G; De Smet R; Lameire N; Dhondt A; Duym P; Vanholder R
    Nephrol Dial Transplant; 2000 Jan; 15(1):50-7. PubMed ID: 10607767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of the super-flux cellulose triacetate dialyser membrane on the removal of non-protein-bound and protein-bound uraemic solutes.
    De Smet R; Dhondt A; Eloot S; Galli F; Waterloos MA; Vanholder R
    Nephrol Dial Transplant; 2007 Jul; 22(7):2006-12. PubMed ID: 17468506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Removal of uraemic retention solutes in standard bicarbonate haemodialysis and long-hour slow-flow bicarbonate haemodialysis.
    Basile C; Libutti P; Di Turo AL; Casino FG; Vernaglione L; Tundo S; Maselli P; De Nicolò EV; Ceci E; Teutonico A; Lomonte C
    Nephrol Dial Transplant; 2011 Apr; 26(4):1296-303. PubMed ID: 20813765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein-bound uraemic toxin removal in haemodialysis and post-dilution haemodiafiltration.
    Krieter DH; Hackl A; Rodriguez A; Chenine L; Moragues HL; Lemke HD; Wanner C; Canaud B
    Nephrol Dial Transplant; 2010 Jan; 25(1):212-8. PubMed ID: 19755476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigations on clinico-chemical correlations in uraemic polyneuritis.
    Man NK; Cueuille G; Zingraff J; Drueke T; Jungers P; Sausse A; Billon JP; Funck-Brentano JL
    Proc Eur Dial Transplant Assoc; 1975; 11():214-21. PubMed ID: 1197256
    [No Abstract]   [Full Text] [Related]  

  • 9. Paired filtration-dialysis (PFD): a separate convective-diffusive system for extracorporeal blood purification in uraemic patients.
    Ghezzi PM; Zucchelli P; Ringoir S; Nigrelli S; Santoro A; Gervasio R; Sanz Moreno C; Vanholder R; Botella J
    Adv Exp Med Biol; 1987; 223():267-75. PubMed ID: 3328955
    [No Abstract]   [Full Text] [Related]  

  • 10. Chromatographic analysis of middle molecules in plasma ultrafiltrates of uraemic patients.
    Popławski A; Myśliwiec M
    Nephrol Dial Transplant; 1993; 8(2):188. PubMed ID: 8384345
    [No Abstract]   [Full Text] [Related]  

  • 11. Renal versus continuous versus intermittent therapies for removal of uremic toxins.
    Clark WR; Henderson LW
    Kidney Int Suppl; 2001 Feb; 78():S298-303. PubMed ID: 11169030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Removal of uraemic toxins by haemofiltration with different membranes. The benefit of regenerating haemofiltrate using a newly developed system.
    Jörstad S; Smeby LC; Wideröe TE; Berg KJ
    Proc Eur Dial Transplant Assoc; 1979; 16():212-7. PubMed ID: 548983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should dialysis modalities be designed to remove specific uremic toxins?
    Baurmeister U; Vienken J; Ward RA
    Semin Dial; 2009; 22(4):454-7. PubMed ID: 19709001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin/cytokine profiles in haemodialysis and in continuous peritoneal dialysis.
    Jacobs P; Glorieux G; Vanholder R
    Nephrol Dial Transplant; 2004 Aug; 19 Suppl 5():V41-45. PubMed ID: 15284359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous Reduction of Protein-Bound Uraemic Toxins with Improved Oxidative Stress by Using the Oral Charcoal Adsorbent AST-120 in Haemodialysis Patients.
    Yamamoto S; Kazama JJ; Omori K; Matsuo K; Takahashi Y; Kawamura K; Matsuto T; Watanabe H; Maruyama T; Narita I
    Sci Rep; 2015 Sep; 5():14381. PubMed ID: 26395517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The middle-molecule hypothesis 30 years after: lost and rediscovered in the universe of uremic toxicity?
    Vanholder R; Van Laecke S; Glorieux G
    J Nephrol; 2008; 21(2):146-60. PubMed ID: 18446708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Removal of uraemic plasma factor(s) using different dialysis modalities reduces phosphatidylserine exposure in red blood cells.
    Bonomini M; Ballone E; Di Stante S; Bucciarelli T; Dottori S; Arduini A; Urbani A; Sirolli V
    Nephrol Dial Transplant; 2004 Jan; 19(1):68-74. PubMed ID: 14671041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review on uraemic toxins III: recommendations for handling uraemic retention solutes in vitro--towards a standardized approach for research on uraemia.
    Cohen G; Glorieux G; Thornalley P; Schepers E; Meert N; Jankowski J; Jankowski V; Argiles A; Anderstam B; Brunet P; Cerini C; Dou L; Deppisch R; Marescau B; Massy Z; Perna A; Raupachova J; Rodriguez M; Stegmayr B; Vanholder R; Hörl WH;
    Nephrol Dial Transplant; 2007 Dec; 22(12):3381-90. PubMed ID: 17724037
    [No Abstract]   [Full Text] [Related]  

  • 19. Middle molecules in uraemia.
    Fürst P; Asaba M; Gordon A; Zimmerman L; Bergström J
    Proc Eur Dial Transplant Assoc; 1975; 11():417-26. PubMed ID: 1105558
    [No Abstract]   [Full Text] [Related]  

  • 20. Neurological manifestations of uraemia and chronic dialysis.
    Tzamaloukas AH; Agaba EI
    Niger J Med; 2004; 13(2):98-105. PubMed ID: 15293824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.